(Q33374576)

26 July 2017

title

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

1 reference

6

Dennis S Chi

1 reference

26 July 2017

10

Carol Aghajanian

1 reference

26 July 2017

Martee L Hensley

1

1 reference

26 July 2017

Don Dizon

2

1 reference

26 July 2017

Felicia Derosa

3

1 reference

26 July 2017

Ennapadam Venkatraman

4

1 reference

26 July 2017

Paul Sabbatini

5

1 reference

26 July 2017

Jakob Dupont

7

1 reference

26 July 2017

A Dimitrios Colevas

8

1 reference

26 July 2017

David Spriggs

9

1 reference

26 July 2017

publication date

16 March 2007

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

25

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

335-341

1 reference

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

26 July 2017

cites work

1 reference

12 December 2020

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

12 December 2020

Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients

1 reference

12 December 2020

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

12 December 2020

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

1 reference

12 December 2020

An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines

1 reference

12 December 2020

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

1 reference

12 December 2020

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

12 December 2020

The clinical development of new mitotic inhibitors that stabilize the microtubule

1 reference

12 December 2020

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

12 December 2020

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

1 reference

12 December 2020

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

12 December 2020

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

12 December 2020

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

12 December 2020

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study

1 reference

12 December 2020

10.1007/S10637-007-9035-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1029999252

0 references

1 reference